Navigation Links
ANA773 Demonstrates Significant Antiviral Response in Early Clinical Trial in Hepatitis C Patients
Date:8/11/2009

rt of HCV patients who received 2000 mg of ANA773 dosed every other day over a period of 10 days.

About ANA773 and TLR Pharmacology

ANA773 is the Company's oral inducer of endogenous interferons that acts via the toll like receptor 7 (TLR7) pathway. Results from preclinical pharmacology studies have shown that ANA773 can elicit desired immune responses and that the profile of response can be modulated by both dose and schedule of administration. Results of completed 13-week GLP toxicology studies have shown that with every-other-day dosing of ANA773, immune stimulation of a magnitude believed to confer therapeutic potential can be achieved without adverse toxicology findings. The immune stimulation observed with every-other-day dosing of ANA773 in preclinical studies included induction of interferon-alpha and interferon dependent responses at levels that are sustained over 13 weeks of dosing. Furthermore, dose-dependent stimulation of innate immune response in healthy volunteers was observed in Part A of the Phase I clinical trial with ANA773 (presented at EASL, 2009).

About Anadys

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C. The Company believes hepatitis C represents a large unmet medical need in which meaningful improvements in treatment outcomes may be attainable with the introduction of new medicines. The Company is developing ANA598, a non-nucleoside polymerase inhibitor for the treatment of hepatitis C. The Company has also investigated the potential of ANA773, an oral, small-molecule inducer of endogenous interferons that acts via the Toll-like receptor 7, or TLR7, pathway in hepatitis C.

Safe Harbor Statement

Statements in this press release that are not strictly historical
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Fruitfly Model of a Neuropathic Disease Demonstrates Novel Role for Proteins in the Family of aTyr Pharmas Product Class
2. Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases
3. Thiarabine Demonstrates a Reduction of Both Inflammatory and Erosive Disease Parameters in Rheumatoid Arthritis
4. Vantia Therapeutics Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia
5. Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R)
6. Study Demonstrates Efficacy of Pitavastatin in Elderly Patients
7. Semafores SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients
8. Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results
9. Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen
10. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
11. Study Demonstrates Restylane(R) Effect Lasted 18 Months in 97% of Patients With One Repeat Injection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... Research and Markets ( ... "Global Smart Wearable Healthcare Devices and Services ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,The analysts forecast ... market to grow at a CAGR of 30.42% ... covers the present scenario and the growth prospects ...
(Date:3/26/2015)... Md. , March 26, 2015  RegeneRx Biopharmaceuticals, ... it has received a patent acceptance notice from the ... 4 (TB4) to prevent or reduce tissue damage caused ... the case when cardiac vessels are opened after a ... when treating stroke victims. Damage can be ...
(Date:3/26/2015)...  Becton, Dickinson and Company (NYSE: BDX ) ... exchange all validly tendered and accepted notes of the ... subsidiary of BD, for notes to be issued by ... Statement on Form S-4 (the "Registration Statement") relating to ... the Securities and Exchange Commission ("SEC") on March 26, ...
Breaking Medicine Technology:Global Smart Wearable Healthcare Devices and Services Market 2015-2019 WITH Apple, At&T, Ee, Google, Samsung, Sprint, Telefonica & T-Mobile Dominating 2RegeneRx Receives Israeli Patent Acceptance Notice for the Use of TB4 To Prevent Tissue Damage Associated with Heart Attack and Stroke Treatments 2RegeneRx Receives Israeli Patent Acceptance Notice for the Use of TB4 To Prevent Tissue Damage Associated with Heart Attack and Stroke Treatments 3Becton, Dickinson and Company to Commence Exchange Offers 2Becton, Dickinson and Company to Commence Exchange Offers 3Becton, Dickinson and Company to Commence Exchange Offers 4Becton, Dickinson and Company to Commence Exchange Offers 5
... 7, 2011 Intellect Neurosciences, Inc. (OTCBB: ILNS) a ... and multiple licenses with major pharmaceutical companies covering products ... Dr. Daniel Chain, Ph.D., Chairman and CEO will be ... Dr. Chain will be discussing the state of the ...
... The U.S. Food and Drug Administration and the ... a "parallel review" pilot program for concurrent review of ... (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... today, issued procedures for voluntary participation and guiding principles ...
Cached Medicine Technology:Intellect Neurosciences CEO to be Featured on Wall Street Reporter 2FDA, CMS Launch Pilot Program for Voluntary Parallel Review of Innovative Devices 2
(Date:3/26/2015)... Dr. Rod J. Rohrich, who served as ... and has trained over 6500 surgeons through these meetings ... medicine (EBM), that is, the optimization of decision making ... often hear from rhinoplasty surgeons who describe ... not trying to stifle these discussions, we do want ...
(Date:3/26/2015)... UC Davis will establish a prestigious, leading-edge center ... A Silvio O. Conte Center for Basic or Translational ... the United States. , The center will be funded ... of Mental Health, which will allow UC Davis’ Conte ... of schizophrenia may be dysregulation of immune molecules that ...
(Date:3/26/2015)... Scott Sullivan and Frank DellaCroce, Co-Founders of the ... St. Charles Surgical Hospital (SCSH) in New ... Oncologist Dr. William Karl Ordoyne has joined their highly ... oncologist Alan Stolier, M.D., FACS and the team of ... M.D., FACS; Chris Trahan, M.D., FACS; M. Whitten Wise, ...
(Date:3/26/2015)... (PRWEB) March 26, 2015 Building ... of continuing medical education, the Cardiometabolic Risk ... Medicine at Tulane University are proud to ... Medicine. The interdisciplinary program , which ... credential, is designed for physicians, nurse practitioners, physician ...
(Date:3/26/2015)... March 26, 2015 Visiting Nurse ... their 18th annual gala fundraiser, Lighting the Way, Brightening ... p.m. at The Madison Hotel in Morristown, NJ. ... entertainment by renowned musician Rio Clemente, delightful cuisine, an ... and Dave Hertzel. Additionally, two prestigious awards will be ...
Breaking Medicine News(10 mins):Health News:Dr. Rod Rohrich Explores Evidence Based Innovations and Safety at the 32nd Annual Dallas Rhinoplasty Symposium 2Health News:UC Davis Receives $10 Million Grant to Establish Center to Study Schizophrenia 2Health News:UC Davis Receives $10 Million Grant to Establish Center to Study Schizophrenia 3Health News:UC Davis Receives $10 Million Grant to Establish Center to Study Schizophrenia 4Health News:Surgical Oncologist Joins Center for Restorative Breast Surgery and St. Charles Surgical Hospital 2Health News:Surgical Oncologist Joins Center for Restorative Breast Surgery and St. Charles Surgical Hospital 3Health News:Certified Culinary Medicine Specialist Program Jointly Launched by Goldring Center for Culinary Medicine at Tulane University and Cardiometabolic Risk Summit 2Health News:Certified Culinary Medicine Specialist Program Jointly Launched by Goldring Center for Culinary Medicine at Tulane University and Cardiometabolic Risk Summit 3Health News:Morristown VNA Fundraiser to Honor Distinguished Community Members 2
... Human ... , , ... (PRWEB) April 6, 2010 -- Human Touch , the U.S. market leader of innovative ... the World Federation of Chiropractic (WFC) for its massage chairs as a valid supplement to ...
... (short for sarcoma) is a family of proto-oncogenic tyrosine ... the most common malignant cancer in children. Src represents ... A recent study shows that pyrazolo-[3,4-d]pyrimidine-derivatives, designed to ... cell cycle and causing cancer cell death in medulloblastoma. ...
... Swedish medical university Karolinska Institutet provides evidence that basic ... that also exist in the most primitive vertebrates, such ... an investigation into the limbic striatum, one of the ... to learn movements, consciously and unconsciously, through repetition. ...
... ... massage. There are many other massages and spa services that customers can enjoy ... ... Envy’s New Jersey franchise group ( http://www.massageenvy.com/regions/NJ/Northern-New-Jersey.aspx ), a subsection of franchisees of ...
... and sedatives up 65 percent in U.S., study finds ... by accidental and intentional abuse of prescription sedatives, tranquilizers ... last decade, new research reveals. , Hospital stays from ... Percocet) and sedatives (such as Valium and Ativan) jumped ...
... ... ... Noni International (TNI) announced a new quarter of a million dollar challenge to all ... industry will measure up to Tahitian Noni Bioactive Beverages., , , , ,Tahitian Noni International ...
Cached Medicine News:Health News:Human Touch Massage Chairs Receive Exclusive Endorsement from World Federation of Chiropractic 2Health News:Human Touch Massage Chairs Receive Exclusive Endorsement from World Federation of Chiropractic 3Health News:Human Touch Massage Chairs Receive Exclusive Endorsement from World Federation of Chiropractic 4Health News:Human Touch Massage Chairs Receive Exclusive Endorsement from World Federation of Chiropractic 5Health News:New pyrimidine compounds may lead to improved treatments for childhood brain cancer 2Health News:Unconscious learning uses old parts of the brain 2Health News:Massage Envy New Jersey offers $49, 1-Hour Therapeutic Massage 2Health News:Prescription Drug Abuse Sending More to Hospitals 2Health News:Prescription Drug Abuse Sending More to Hospitals 3Health News:Quarter of a Million Dollar Superfruit Challenge Announced 2
Used as a percutaneous entry needle to introduce wire guides. The coaxial design reduces potential A.V. malformations. Supplied sterile in peel-open packages. Intended for one-time use....
Used under fluoroscopy for initial location and positioning of the renal collecting system throughout a percutaneous nephrostomy. Supplied sterile in peel-open packages. Intended for one-time use....
Used under fluoroscopy for initial location and positioning of the renal collecting system throughout a percutaneous nephrostomy. Supplied sterile in peel-open packages. Intended for one-time use....
The Linvatec 3mm and 5mm Universal Light Guides are autoclavable. They offer flexibility, superior light transmission, and universal fittings in a lightweight package....
Medicine Products: